Viewing Study NCT05955092


Ignite Creation Date: 2025-12-24 @ 3:51 PM
Ignite Modification Date: 2025-12-29 @ 9:45 PM
Study NCT ID: NCT05955092
Status: UNKNOWN
Last Update Posted: 2023-07-21
First Post: 2023-07-04
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma
Sponsor: Peking Union Medical College Hospital
Organization:

Study Overview

Official Title: Exploring the Application of 3D Bioprinting Technology in Constructing Preclinical Models of Pancreatic Cancer for Drug Sensitivity Testing and Its Significance in Personalized Treatment
Status: UNKNOWN
Status Verified Date: 2023-07
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this observational study is to test the application value of 3D bioprinting technology in personalized treatment of pancreatic cancer.

The main questions it aims to answer are:

* Can 3D bioprinting technology be successfully applied to establish preclinical models of pancreatic cancer?
* Can 3D bioprinted preclinical models of pancreatic cancer be applied to personalized treatment of pancreatic cancer?

Participants will have tumor tissue collected to extract primary tumor cells for the establishment of in vitro preclinical models, which will be used for drug sensitivity testing.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: